OverviewSuggest Edit

Intersect ENT is dedicated to improving the quality of life for patients with ear, nose and throat conditions. The Company markets the first and only drug-releasing sinus implants, PROPEL and PROPEL mini, which are clinically proven to improve surgical outcomes for patients with chronic sinusitis. The products release an advanced steroid with anti-inflammatory properties directly into the sinus lining, then dissolve, maintaining the open passages created in ethmoid sinus surgery. In addition, Intersect ENT is pursuing clinical trials designed to support expanded indications and to assess two new investigational drug-eluting implants to provide ENT physicians with additional options to treat patients with chronic sinusitis less invasively and more cost effectively. Chronic sinusitis is an inflammatory condition leading to debilitating symptoms and chronic infections, and is one of the most costly conditions to U.S. employers.
TypePublic
Founded2003
HQMenlo Park, US
Websiteintersectent.com
Employee Ratings2.7

Locations

Intersect ENT is headquartered in
Menlo Park, United States

Location Map

Latest Updates

Employees (est.) (Dec 2019)402(+3%)
Job Openings17
Revenue (FY, 2019)$109.1 M
Share Price (Sept 2020)$16.2 (+2%)
Cybersecurity ratingCMore

Key People/Management at Intersect ENT

Thomas A. West

Thomas A. West

President and Chief Executive Officer
David Lehman

David Lehman

Executive Vice President, General Counsel & Corporate Secretary
Gwen Carscadden

Gwen Carscadden

Chief People Officer
Rich Kaufman

Rich Kaufman

Senior Vice President and Chief Operating Officer
Christine Kowalski

Christine Kowalski

Executive Vice President & Chief Operating Officer
Randy Meier

Randy Meier

Executive Vice President & Chief Financial Officer
Show more

Intersect ENT Office Locations

Intersect ENT has an office in Menlo Park
Menlo Park, US (HQ)
1555 Adams Dr
Show all (1)

Intersect ENT Financials and Metrics

Intersect ENT Revenue

Embed Graph
View revenue for all periods
Intersect ENT's revenue was reported to be $109.14 m in FY, 2019
USD

Revenue (Q2, 2020)

9.8m

Gross profit (Q2, 2020)

2.4m

Gross profit margin (Q2, 2020), %

24.8%

Net income (Q2, 2020)

(23.1m)

EBIT (Q2, 2020)

(21.1m)

Market capitalization (25-Sept-2020)

530.8m

Closing stock price (25-Sept-2020)

16.2

Cash (30-Jun-2020)

29.5m

EV

574.8m
Intersect ENT's current market capitalization is $530.8 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

38.6m61.6m78.7m96.3m108.5m109.1m

Revenue growth, %

60%28%

Cost of goods sold

10.2m12.3m13.0m15.5m22.6m21.8m

Gross profit

28.4m49.3m65.7m80.8m85.9m87.4m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

8.6m9.1m13.4m15.2m14.2m16.7m19.3m18.5m20.5m24.0m22.3m24.7m26.3m24.7m26.7m26.7m24.1m19.8m9.8m

Cost of goods sold

2.3m2.6m2.8m2.9m2.9m3.2m3.1m2.8m2.9m3.7m3.8m5.5m5.6m5.2m4.6m5.0m4.9m6.4m7.4m

Gross profit

6.2m6.5m10.6m12.3m11.4m13.5m16.2m15.7m17.6m20.3m18.5m19.2m20.7m19.5m22.0m21.6m19.2m13.4m2.4m

Gross profit Margin, %

73%72%79%81%80%81%84%85%86%85%83%78%79%79%83%81%80%68%25%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

13.4m34.8m9.9m19.8m9.5m20.7m

Accounts Receivable

8.3m11.5m14.4m16.6m19.6m19.1m

Prepaid Expenses

2.9m2.7m2.3m

Inventories

951.0k1.5m1.3m8.5m11.6m17.0m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(18.4m)(26.6m)(25.2m)(16.4m)(22.9m)(43.0m)

Depreciation and Amortization

1.2m1.5m1.9m2.7m

Inventories

(541.0k)(544.0k)(1.7m)(2.9m)(2.5m)(5.1m)

Accounts Payable

645.0k(230.0k)1.2m203.0k2.1m(1.2m)
USDQ2, 2014

Financial Leverage

-0.2 x
Show all financial metrics

Intersect ENT Operating Metrics

Intersect ENT's Patients was reported to be 150 k in FY, 2016.
FY, 2016

Accounts

2.40 k

Patents (US)

30

Patents Pending

37

Patients

150 k
Show all operating metrics

Intersect ENT Cybersecurity Score

Cybersecurity ratingPremium dataset

C

77/100

SecurityScorecard logo

Intersect ENT Online and Social Media Presence

Embed Graph

Intersect ENT Frequently Asked Questions

  • When was Intersect ENT founded?

    Intersect ENT was founded in 2003.

  • Who are Intersect ENT key executives?

    Intersect ENT's key executives are Thomas A. West, David Lehman and Gwen Carscadden.

  • How many employees does Intersect ENT have?

    Intersect ENT has 402 employees.

  • What is Intersect ENT revenue?

    Latest Intersect ENT annual revenue is $109.1 m.

  • What is Intersect ENT revenue per employee?

    Latest Intersect ENT revenue per employee is $271.5 k.

  • Who are Intersect ENT competitors?

    Competitors of Intersect ENT include NxStage Medical, ResMed and Avinger.

  • Where is Intersect ENT headquarters?

    Intersect ENT headquarters is located at 1555 Adams Dr, Menlo Park.

  • Where are Intersect ENT offices?

    Intersect ENT has an office in Menlo Park.

  • How many offices does Intersect ENT have?

    Intersect ENT has 1 office.